From Wikipedia, the free encyclopedia
Designer drug
CUMYL-CB-MEGACLONE
|
|
Legal status |
|
---|
|
2,5-Dihydro-2-(1-methyl-1-phenylethyl)-5-(cyclobutylmethyl)-1H-pyrido[4,3-b]indol-1-one
|
|
Formula | C25H26N2O |
---|
Molar mass | 370.496 g·mol−1 |
---|
3D model (
JSmol) | |
---|
CC(C)(c1ccccc1)N5C=Cc4n(CC2CCC2)c3ccccc3c4C5=O
|
InChI=1S/C25H26N2O/c1-25(2,19-11-4-3-5-12-19)27-16-15-22-23(24(27)28)20-13-6-7-14-21(20)26(22)17-18-9-8-10-18/h3-7,11-16,18H,8-10,17H2,1-2H Key:XABXFXHKUHKHFO-UHFFFAOYSA-N
|
CUMYL-CB-MEGACLONE (CUMYL-CBMGACLONE, SGT-273) is a
gamma-carboline based
synthetic cannabinoid receptor agonist that has been sold as a
designer drug, first being identified in Hungary in April 2020.
[1]
See also
References
|
---|
Phytocannabinoids (
comparison) | Cannabibutols | |
---|
Cannabichromenes | |
---|
Cannabicyclols | |
---|
Cannabidiols | |
---|
Cannabielsoins | |
---|
Cannabigerols | |
---|
Cannabiphorols | |
---|
Cannabinols | |
---|
Cannabitriols | |
---|
Cannabivarins | |
---|
Delta-8-tetrahydrocannabinols | |
---|
Delta-9-tetrahydrocannabinols | |
---|
Delta-10-Tetrahydrocannabinols | |
---|
Miscellaneous cannabinoids | |
---|
Active metabolites | |
---|
|
---|
Endocannabinoids | |
---|
Synthetic cannabinoid receptor agonists / neocannabinoids | Classical cannabinoids (dibenzopyrans) | |
---|
Non-classical cannabinoids | |
---|
Adamantoylindoles | |
---|
Benzimidazoles | |
---|
Benzoylindoles | |
---|
Cyclohexylphenols | |
---|
Eicosanoids | |
---|
Hydrocarbons | |
---|
Indazole carboxamides | |
---|
Indazole-3- carboxamides | |
---|
Indole-3-carboxamides | |
---|
Indole-3-carboxylates | |
---|
Naphthoylindazoles | |
---|
Naphthoylindoles | |
---|
Naphthoylpyrroles | |
---|
Naphthylmethylindenes | |
---|
Naphthylmethylindoles | |
---|
Phenylacetylindoles | |
---|
Pyrazolecarboxamides | |
---|
Pyrrolobenzoxazines | |
---|
Quinolinyl esters | |
---|
Tetramethylcyclo- propanoylindazoles | |
---|
Tetramethylcyclo- propanoylindoles | |
---|
Tetramethylcyclo- propylindoles | |
---|
Others | |
---|
|
---|
Allosteric
CBRTooltip Cannabinoid receptor
ligands | |
---|
Endocannabinoid enhancers (inactivation inhibitors) | |
---|
Anticannabinoids (antagonists/inverse agonists/antibodies) | |
---|
|
|
---|
Receptor (
ligands) |
CB1Tooltip Cannabinoid receptor type 1 | Agonists (abridged,
full list) | |
---|
Inverse agonists | |
---|
Antagonists | |
---|
|
---|
CB2Tooltip Cannabinoid receptor type 2 | Agonists |
-
2-AG
-
2-AGE (noladin ether)
-
3,3'-Diindolylmethane
-
4-O-Methylhonokiol
-
α-Amyrin · β-Amyrin
-
A-796,260
-
A-834,735
-
A-836,339
-
AM-1172
-
AM-1221
-
AM-1235
-
AM-1241
-
AM-2232
-
Anandamide
-
AZ-11713908
-
Cannabinol
-
Caryophyllene
-
CB-13
-
CBS-0550
-
CP 55,940
-
GW-405,833 (L-768,242)
-
GW-842,166X
-
HU-308
-
JTE 7-31
-
JWH-007
-
JWH-015
-
JWH-018
-
JWH-73
-
JWH-133
-
L-759,633
-
L-759,656
-
Lenabasum (anabasum)
-
Magnolol
-
MDA-19
-
Nabitan
-
NADA
-
Olorinab (APD-371)
-
PF-03550096
-
S-444,823
-
SER-601
-
Serinolamide A
-
UR-144
-
Tedalinab
-
THC (dronabinol)
-
THCV
-
Tetrahydromagnolol
-
Virodhamine
|
---|
Antagonists | |
---|
|
---|
NAGly (
GPR18) | |
---|
GPR55 | |
---|
GPR119 | |
---|
|
---|
Transporter (
modulators) |
eCBTsTooltip Endocannabinoid transporter | |
---|
|
---|
Enzyme (
modulators) | |
---|
Others |
- Others:
2-PG (directly potentiates activity of 2-AG at CB1 receptor)
-
ARN-272 (FAAH-like anandamide transporter inhibitor)
|
---|
|